Human Protein Turnover Project

Human Protein Turnover Project - HuPTuP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47497

Enrollment

Registered

2015-01-07

Start date

2015-05-04

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human tissue protein turnover

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18 to 85 years; - Compos mentis; - Surgical intervention for oesophagus carcinoma, colon carcinoma, aortic valve insufficiency, lung carcinoma, renal cell carcinoma, epilepsy and hip fracture; - Written informed consent.

Exclusion criteria

Exclusion criteria: - Co-morbidities and neuromuscular disorders of the lower limbs severely interacting with mobility with limited or no opportunity for improvement (e.g. cerebral palsy); - Peripheral arterial disease Fontaine III or IV; - Chronic obstructive pulmonary disease (COPD) GOLD III or IV; - Use of systemic steroids in the past four weeks, other than indicated for the specific type of surgery; - Use anti-inflammatory biologicals (e.g. TNF-alfa blockers) in the past four weeks; - Phenylketonuria (PKU); - Surgical intervention in the past four weeks; - Insulin dependent diabetes mellitus; - Total parenteral nutrition at day of surgery; - Pregnancy; - Neoadjuvant chemo- or radiotherapy in the past four weeks.

Design outcomes

Primary

Measure	Time frame
Protein synthesis rates, expressed as fractional synthetic rate (FSR) [%/h] and enrichments [mole percent excess, MPE] in skin, bone, heart, lung, kidney, oesophagus, stomach, colon, brain and vastus lateralis muscle tissue. Protein synthesis is calculated from: - Plasma and organ tissue free phenylalanine concentration; - Plasma enrichment of L-[ring-13C6]-phenylalanine; - Organ tissue protein bound enrichment of L-[ring-13C6]-phenylalanine; - L-[ring-13C6]-phenylalanine enrichment of the organ tissue free amino acid pool.	—

Measure

Time frame

Protein synthesis rates, expressed as fractional synthetic rate (FSR) [%/h] and enrichments [mole percent excess, MPE] in skin, bone, heart, lung, kidney, oesophagus, stomach, colon, brain and vastus lateralis muscle tissue. Protein synthesis is calculated from: - Plasma and organ tissue free phenylalanine concentration; - Plasma enrichment of L-[ring-13C6]-phenylalanine; - Organ tissue protein bound enrichment of L-[ring-13C6]-phenylalanine; - L-[ring-13C6]-phenylalanine enrichment of the organ tissue free amino acid pool.

—

Secondary

Measure	Time frame
Protein synthesis rates, expressed as fractional synthetic rate (FSR) [%/h] and enrichments [mole percent excess, MPE] in tumour tissue. Protein syntesis is calculated from: - Plasma and tumour tissue free phenylalanine concentration; - Plasma enrichment of L-[ring-13C6]-phenylalanine; - Tumour tissue protein bound enrichment of L-[ring-13C6]-phenylalanine; - L-[ring-13C6]-phenylalanine enrichment of the tumour tissue free amino acid pool.	—

Measure

Time frame

Protein synthesis rates, expressed as fractional synthetic rate (FSR) [%/h] and enrichments [mole percent excess, MPE] in tumour tissue. Protein syntesis is calculated from: - Plasma and tumour tissue free phenylalanine concentration; - Plasma enrichment of L-[ring-13C6]-phenylalanine; - Tumour tissue protein bound enrichment of L-[ring-13C6]-phenylalanine; - L-[ring-13C6]-phenylalanine enrichment of the tumour tissue free amino acid pool.

—

Countries

Netherlands

Outcome results